Decoding Multiple Myeloma: Can a Simple Blood Test Predict Outcomes?
"New research explores how neuron-specific enolase (NSE) levels could revolutionize diagnosis and treatment monitoring for multiple myeloma, offering hope for better patient outcomes."
Multiple myeloma (MM), a cancer of plasma cells in the bone marrow, presents significant challenges in treatment and monitoring. Currently, doctors rely on bone marrow biopsies, protein level checks, and imaging to track the disease. Finding reliable and less invasive markers to predict how well a patient will respond to treatment and how the disease will progress is crucial.
Recent research has focused on neuron-specific enolase (NSE), an enzyme found in nerve and endocrine tissues, as a potential marker in MM. While traditionally used in lung cancer diagnostics, its role in MM is now being explored. Higher NSE levels have been linked to poorer outcomes in some cancers, prompting scientists to investigate its significance in myeloma.
This article delves into a study that examines NSE levels in MM patients before and after chemotherapy. It seeks to determine if NSE can serve as a valuable biomarker for diagnosis, treatment evaluation, and predicting the course of the disease, potentially leading to more personalized and effective treatment strategies.
Current Burden of Myeloma
SEER reports an age-adjusted myeloma incidence rate of 7.4 per 100,000 men and women per year, based on cases from 2019–2023. The corresponding death rate was 2.8 per 100,000 per year, based on deaths from 2020–2024. A separate serial cross-sectional study examined multiple myeloma incidence and mortality trends in the United States from 1999 to 2020 using the SEER 12 database.
Limits of Conventional Assessment
Traditional staging and biomarker approaches remain important for diagnosis and prognosis, but the listed reviews describe meaningful limitations. The International Staging System was introduced in part because the Durie-Salmon system depends on subjective assessment of the extent of bone disease. Blood-based MRD testing by mass spectrometry may require a baseline sample to identify clonotypic peptides, a patient-specific workflow, and may not detect post-translational modifications or other monoclonal proteins. Recent biomarker reviews therefore emphasize integrating advanced platforms to address limitations in current diagnostic and therapeutic models.
From First Reports to Genomic Evolution
The first documented case of multiple myeloma was reported by Samuel Solly in 1844. Historical milestones include the definition of Bence Jones proteinuria, characterization of tumoral plasma cells and serum globulins, and the contribution of Jan Waldenstrom. More recently, next-generation sequencing has portrayed multiple myeloma as a complex hematologic cancer shaped by multiple mutational processes and key driver events. A genomic perspective also describes precursor states that may precede diagnosis by decades, with both germline variants and multiple-myeloma-specific loci influencing initial transformation.
How Can NSE Levels Help Manage Multiple Myeloma?
The study involved measuring NSE levels in 52 MM patients, comparing them to healthy individuals and patients with lung cancer. Researchers used a highly sensitive method called electrochemiluminescence immunoassay (ECLIA) to detect NSE in blood samples. They also examined bone marrow biopsies from MM patients to assess NSE expression directly in plasma cells.
- MM patients often have elevated NSE levels compared to healthy individuals.
- NSE levels tend to decrease after successful chemotherapy.
- Higher NSE levels correlate with higher levels of β2-MG, indicating more advanced disease.
- Changes in NSE levels appear to be linked to how long a patient stays in remission (progression-free survival).
An Evolving Research Landscape
Recent research continues to examine how blood-based measurements and other biomarkers might improve multiple myeloma diagnosis, risk assessment, and treatment monitoring. Reviews suggest that these approaches are still developing rather than replacing every established clinical assessment. Their eventual value will depend on validation, reproducibility, and integration with broader clinical information.
Biomarker Promise and Uncertainty
Neuron-specific enolase, or NSE, has been investigated in multiple myeloma as a possible tumor marker and indicator of disease progression and treatment efficacy. The available source material frames this as an evaluation of clinical value, not as proof that NSE can reliably replace established measures. At the same time, a 2026 review argues that next-generation biomarker platforms may help overcome limitations in current diagnostic and therapeutic models, underscoring that the field remains in transition.
Established and Emerging Markers
Established and novel prognostic biomarkers are used to stratify patients with high-risk smoldering multiple myeloma who may progress rapidly to overt disease. However, the listed review notes that these biomarkers depend on tumor-burden measurements, and additional studies are needed to improve stratification. A separate review surveys newer biomarkers for multiple myeloma diagnosis, prognosis, and management while also highlighting their limitations and areas for improvement.
The Future of MM Treatment: Personalizing Care with NSE
The study indicates that monitoring NSE levels in MM patients holds significant promise. By tracking these levels, clinicians may gain a better understanding of treatment efficacy and disease progression. This could lead to more informed decisions about when to adjust therapy, potentially improving long-term outcomes.
NSE as a Candidate Biomarker
The available PLOS source describes a study designed to examine the relationship between neuron-specific enolase and multiple myeloma. Its stated aim was to assess whether NSE could support diagnosis, treatment evaluation, and prognosis. This framing identifies NSE as a candidate biomarker under investigation rather than an established standalone predictor of outcomes.
Biomarkers for the Era of Novel Therapies
The growing number and complexity of drug classes for multiple myeloma have improved response rates, increasing the need for clinically useful biomarkers that remain relevant alongside novel therapies. Current research describes multiple myeloma as a clonal malignancy of plasma cells that migrate to the bone marrow, where malignant transformation contributes to disease progression. Market projections reported by one source estimate that the multiple myeloma market could reach US$53.47 billion by 2033, although that figure is a market projection rather than a clinical-outcome measure.
Beyond a Single Test
A simple blood test may eventually contribute to outcome prediction, but biomarker research generally addresses a complex disease rather than a single universal signal. Any clinically useful approach will likely need validation across different patients, disease stages, and treatment settings. The broader challenge is translating promising research measurements into reliable tools that complement, rather than oversimplify, clinical decision-making.
Biomarkers and Patient Outcomes
A study using comprehensive health-insurance data from Korea examined patients who progressed to multiple myeloma after detection of a precursor state, linking biomarker-informed disease history with real-world survival research. Another report found that patients with high circulating extracellular-vesicle cargo, or EVcargo, had a 12-times-increased risk of dying. High EVcargo was also associated with immunoparesis, serum free light-chain findings, and the duration of treatment response. These findings suggest that blood-based markers could eventually help connect disease biology with patient-level prognosis, although the clinical role of EVcargo still requires further evaluation.
While these findings are encouraging, further research is needed to fully validate the role of NSE in MM management. Larger studies with longer follow-up periods are necessary to confirm its prognostic value and explore how different treatment approaches affect NSE levels. Understanding these dynamics could pave the way for personalized treatment strategies tailored to individual patient profiles.
Ultimately, incorporating NSE monitoring into routine clinical practice could transform how MM is diagnosed, treated, and managed. Its ease of detection and relatively low cost make it a potentially valuable tool for improving patient care and advancing the fight against this challenging cancer.